Mirae Asset Global Etfs Holdings Ltd. Viridian Therapeutics, Inc.\De Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $43.4 Billion
- Q1 2025
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 49,276 shares of VRDN stock, worth $685,921. This represents 0.0% of its overall portfolio holdings.
Number of Shares
49,276
Previous 48,400
1.81%
Holding current value
$685,921
Previous $927,000
28.37%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding VRDN
# of Institutions
189Shares Held
79.6MCall Options Held
92.2KPut Options Held
55.2K-
Deep Track Capital, LP Greenwich, CT5.38MShares$74.9 Million2.54% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$66.4 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.7MShares$65.4 Million5.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.56MShares$63.5 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$54 Million12.64% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $555M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...